[C9orf72](/entities/c9orf72) hexanucleotide repeat expansion is the most common genetic cause of both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), accounting for approximately 30-40% of familial ALS cases and 20-25% of familial FTD cases. This investment landscape summarizes therapeutic approaches targeting C9orf72 pathology, including antisense oligonucleotides (ASOs), small molecules, and gene therapy strategies. The field has advanced significantly with multiple clinical-stage programs and a robust preclinical pipeline targeting the three main pathological mechanisms: loss of function, RNA foci formation, and dipeptide repeat protein (DPR) toxicity. [@dejesushernandez2011]
Overview
This page summarizes R&D investment signals for C9orf72-targeted therapeutics in ALS and FTD. The C9orf72 gene encodes a DENN domain protein involved in endolysosomal trafficking and [autophagy](/entities/autophagy), and its expansion leads to both loss-of-function and gain-of-toxicity mechanisms. Therapeutic development focuses on: (1) reducing toxic RNA foci and DPRs; (2) restoring C9orf72 protein function; (3) addressing downstream effects including nucleocytoplasmic transport defects and mitochondrial dysfunction. [@renton2011]
Pipeline Summary
Clinical Trials
...
Executive Summary
[C9orf72](/entities/c9orf72) hexanucleotide repeat expansion is the most common genetic cause of both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), accounting for approximately 30-40% of familial ALS cases and 20-25% of familial FTD cases. This investment landscape summarizes therapeutic approaches targeting C9orf72 pathology, including antisense oligonucleotides (ASOs), small molecules, and gene therapy strategies. The field has advanced significantly with multiple clinical-stage programs and a robust preclinical pipeline targeting the three main pathological mechanisms: loss of function, RNA foci formation, and dipeptide repeat protein (DPR) toxicity. [@dejesushernandez2011]
Overview
This page summarizes R&D investment signals for C9orf72-targeted therapeutics in ALS and FTD. The C9orf72 gene encodes a DENN domain protein involved in endolysosomal trafficking and [autophagy](/entities/autophagy), and its expansion leads to both loss-of-function and gain-of-toxicity mechanisms. Therapeutic development focuses on: (1) reducing toxic RNA foci and DPRs; (2) restoring C9orf72 protein function; (3) addressing downstream effects including nucleocytoplasmic transport defects and mitochondrial dysfunction. [@renton2011]
| Program | Sponsor | Modality | Target | |---|---|---|---| | Multiple programs | Various | Small molecule | DPR aggregation inhibitors | | Various | Academic consortia | Gene therapy | Viral vector delivery | | Several programs | Biotech startups | RNA-targeting | RNA splicing modulators |
Therapeutic Approach Categories
1. Antisense Oligonucleotides (ASOs)
ASOs target the C9orf72 pre-mRNA to reduce the production of toxic dipeptide repeat proteins while preserving normal C9orf72 expression. Key programs include:
BIIB078 (Biogen/Ionis): First-generation ASO targeting the expanded repeat. Completed Phase 1/2 trial but showed limited efficacy, leading to program discontinuation.
WVE-004 (Wave Life Sciences): Stereopure ASO targeting C9orf72 transcript variants. Completed Phase 1/2 with modest results.
Next-generation ASOs: Newer approaches focus on allele-selective targeting and improved CNS delivery.
2. Small Molecule Therapeutics
Small molecules offer oral bioavailability and potential for combination therapy: